News
News

The latest updates from AFAR.

Board Member in the News:  Steven Austad on Longevity Disparity in America in Forbes

Sep 27
2017

Board Member in the News: Steven Austad on Longevity Disparity in America in Forbes

On September 26, 2017, PBS Next Avenue column on Forbes.com featured insights from AFAR Scientific Director Steven N. Austad, PhD, on research that points towards how socioeconomic differences influence disparites in longevity and healthspan for Americans. The article,  “Why America’s Inequality is a Threat to Living Longer,” captured the discussion shared at Stanford University 10th Anniversary Symposium: Celebrating a Decade of Resigning Long Life, where Dr. Austad presented. Dr. Austad references research showing a gap between the haves and have-nots in health now threatens to undermine the progress science has made in lengthening human expectancy —68.2…


View MoreREAD MORE


Grantee in the News: David Holtzman on triple impact of ApoE4 in Nature.

Sep 22
2017

Grantee in the News: David Holtzman on triple impact of ApoE4 in Nature.

On September 20, 2017, Nature published research by 1995 Beeson Scholar David Holtzman, M.D. on two additional ways that the genetic variant ApoE4 impacts neourodeneration linked to Alzheimer’s Disease. ApoE4 has long been understood to be a gentic risk factor for speeding up the development of brain plaques associated with Alzheimer’s. In “ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy,” Holtzman and his co-authors discovered that ApoE4 also worsens tau tangles—another signature of the disease—as well as increases inflammation that kills brain cells. This triple impact of ApoE4 discovered…


View MoreREAD MORE


Grantee in the News: Catherine Kaczorowski receives $5.4m NIA grant

Sep 22
2017

Grantee in the News: Catherine Kaczorowski receives $5.4m NIA grant

On September 18, 2017, the Jackson Laboratory (JAX) announced that AFAR 2014 New Investigator Award in Alzheimer's Disease recipient Catherine Kaczorowski has received a five year, $5.4 million grant from the National Institute on Aging to study cognitive resilience to Alzheimer’s disease. As the Jackson Laboratory reports: The grant will fund research to explore why some people with a family history of Alzheimer’s disease, and even brain changes associated with the disease, nevertheless manage to maintain their cognitive capabilities. Understanding the genetic factors behind this so-called cognitive resilience could provide targets for treatment and prevention of Alzheimer&rsquo…


View MoreREAD MORE


Grantee in the News: Beeson Scholar & Chair Thomas M. Gill on hospice admission in JAGS and Futurity

Sep 18
2017

Grantee in the News: Beeson Scholar & Chair Thomas M. Gill on hospice admission in JAGS and Futurity

  On September 12, 2017, the Journal of the American Geriatrics Society published research co-authored by 1997 Beeson Scholar and current Beeson Program Advisory Committee Chair Thomas M. Gill, MD evaluating the relationship between the presence and number of restricting symptoms and number of disabilities and subsequent admission to hospice at the end of life. In “Distressing Symptoms, Disability, and Hospice Services at the End of Life: Prospective Cohort Study,” Gill and his co-authors found that hospice services appear to be suitably targeted to older persons with the greatest needs at the end of life, although the short duration of…


View MoreREAD MORE


Board member in the News: James Kirkland’s research on screening platform for senolytics in Nature

Sep 18
2017

Board member in the News: James Kirkland’s research on screening platform for senolytics in Nature

On September 4, 2017, Nature Communications published research co-authored by 2012 Glenn/AFAR BIG Award winner and AFAR Board President-Elect James L. Kirkland, MD, PhD, on the use of a screening platform to identify more senolytic drugs. https://www.nature.com/articles/s41467-017-00314-z As reported in “Identification of HSP90 inhibitors as a novel class of senolytics,” Kirkland and his co-authors “established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells”…”to identify novel and more optimal senotherapeutic drugs and combinations.” Senolytic or senotherapeutic…


View MoreREAD MORE


Board member in the News: Today Show spotlights Nir Barzilai and the TAME Trial

Sep 14
2017

Board member in the News: Today Show spotlights Nir Barzilai and the TAME Trial

On Friday, September 8, 2017, NBC Today Show featured a segment with correspondent Maria Shriver spotlighting AFAR Deputy Scientific Director and multiple grantee Nir Barzilai, MD on the potential of the TAME (Targeting Aging with Metformin) Trial . Shot at Dr. Barzilai’s lab at Einstein College of Medicine, the segment explores the potential for drugs that target aging, like Metformin, to extend healthspan. Their dialogue stresses if the FDA considers aging an indication for such interventions, many more promising drugs are ready to be tested and brought to the market, transforming how we can all live healthier as we grow older. …


View MoreREAD MORE


Board Member in the News: David Sinclair on Senolytics in The Boston Herald

Sep 12
2017

Board Member in the News: David Sinclair on Senolytics in The Boston Herald

A September 9, 2017 story in The Boston Herald featured insights by 2000 AFAR Research Grant recipient and Board member David Sinclair, PhD on the potential of senolytic drugs to transform how we age. Despite the article’s claims of “eternal youth” promised by “anti-aging therapies,” Dr. Sinclair speaks on the evidence-based science recently published by 2012 Glenn/AFAR Breakthroughs in Gerontology Award recipient and President-elect James L. Kirkland, MD, PhD in the Journal of the American Geriatrics Society article The Clinical Potential of Senolytic Drugs. Dr. Sinclair notes: “I see a future where people will go…


View MoreREAD MORE


Grantee in the News: David Walker on Mitochondria and longevity in Nature Communications

Sep 07
2017

Grantee in the News: David Walker on Mitochondria and longevity in Nature Communications

On September 6, 2017, Nature Communications published research by 2009 AFAR Research Grant recipient and 2015 Julie Martin Mid-career Awards in Aging Research recipient David W. Walker, PhD. The study, Promoting Drp1-mediated mitochondrial fission in midlife prolongs healthy lifespan of Drosophila melanogaster, involved breaking up enlarged and damaged mitochondria of fruit flies into smaller pieces by increasing their levels of the Drp1 protein. The researchers found the flies became more active and energetic and had more endurance. They also found that female flies lived 20% longer than their typical lifespan, while males lived 12% longer, on average. The research highlights the importance of the protein…


View MoreREAD MORE


Grantee in the News: John Newman on Ketogenic diets in Cell Metabolism

Sep 06
2017

Grantee in the News: John Newman on Ketogenic diets in Cell Metabolism

On September 5, 2017, Cell Metabolism published research by 2014 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar and 2011 Hartford Scholars in Geriatric Medicine recipient, John Newman, MD, PhD, that was picked up by WIRED, Popular Science, and the Guardian. The study, Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice, examined mice with three diets: a normal high-carbohydrate diet, a zero-carbohydrate ketogenic diet, and a high-fat, low-carbohydrate diet that was not ketogenic. The researchers found that ketogenic diet-fed mice had a lower risk of dying as they aged from one to two years old, although their maximum…


View MoreREAD MORE


Board Member in the News: James Kirkland on Senolytic Drugs in CNN and JAGS

Sep 06
2017

Board Member in the News: James Kirkland on Senolytic Drugs in CNN and JAGS

On September 5, 2017, CNN.com featured research by AFAR President-elect and 2012 Glenn/AFAR Breakthroughs in Gerontology Award recipient James Kirkland, MD, PhD, originally published in the Journal of the American Geriatrics Society (JAGS). The article, New class of drugs targets aging to help keep you healthy, describes how Dr. Kirkland and fellow researchers developed the first drugs to effectively remove harmful senescent cells while leaving normal cells unaffected. The study, The Clinical Potential of Senolytic Drugs, found that these drugs could also potentially alleviate frailty in older adults and treat conditions associated with chemotherapy or radiotherapy. Dr. Kirkland explains: “In…


View MoreREAD MORE


Partner Event: Board Members Steven Austad and Thomas Rando present at the Stanford Longevity Center’s 10th Anniversary symposium

Sep 05
2017

Partner Event: Board Members Steven Austad and Thomas Rando present at the Stanford Longevity Center’s 10th Anniversary symposium

On September 21, 2017, AFAR Scientific Director Steven Austad, PhD, and Board Member, 1999 Paul Beeson Career Development Scholar, and 2008 Glenn/AFAR Breakthroughs in Gerontology Award winner Thomas Rando, PhD will present at the Stanford Longevity Center’s 10th Anniversary symposium.    This one-day symposium will be held from 8:00 am - 6:30 pm and explore the advances in the biology of aging that promise to dramatically improve health span and the implications for societies when people live out their full lives. For more information on registration and the program, click here. Steven N. Austad, PhD is a Distinguished Professor and Department Chair…


View MoreREAD MORE


AFAR in the News: UK’s Sunday Times two-part series explores halting the aging process

Sep 05
2017

AFAR in the News: UK’s Sunday Times two-part series explores halting the aging process

On August 27, 2017, the UK-based national publication, The Sunday Times published the second of a two-part series of articles on innovations in aging research featuring AFAR Executive Director Stephanie Lederman, EdM, 2017 Honorary Leadership Award recipient Nathaniel David, PhD, and 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, 1994 AFAR Research Grant recipient, and AFAR Deputy Scientific Director Nir Barzilai, MD. The article, Go hungry for years — or wait for a magic pill, features the AFAR experts sharing insights on the current and future methods of halting the human aging process, including the AFAR-managed Targeting Ageing with Metformin (TAME)…


View MoreREAD MORE


Board Member in the News: Nir Barzilai on the TAME trial in Wall Street Pit

Sep 01
2017

Board Member in the News: Nir Barzilai on the TAME trial in Wall Street Pit

On August 27, 2017, The Wall Street Pit featured 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, 1994 AFAR Research Grant recipient, and AFAR Deputy Scientific Director Nir Barzilai, MD. The article, A Potential Anti-Aging Pill Promises to Extend Life For 5 Cents a Pop, highlights the AFAR-managed TAME trial and the significant efficacy Metformin has proven in past studies.  The article also features Dr. Barzilai’s 2014 TEDTalk: How to die young at a very old age. Read the full Wall Street Pit article here. Nir Barzilai, MD is the Director of the Institute for Aging Research and the…


View MoreREAD MORE




BACK TO TOPBACK TO TOP